Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Because of narrow trial eligibility, results may not be generalizable to a broader HCC population. We sought to evaluate the effectiveness of initial sorafenib versus no treatment among Medicare beneficiaries with advanced HCC
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
Aim: Sorafenib efficacy and safety in advanced hepatocellular carcinoma (HCC) have been demonstrated...
Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Becaus...
Background & AimsThe Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP)...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/135309/1/hep28881-sup-0001-suppinfo.pdf...
Purpose: Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) tri...
BACKGROUND: Prior to the 2008 advent of sorafenib, traditional cytotoxic agents were the therapeutic...
BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHAR...
Introduction: Sorafenib was the first therapy used for systemic treatment of unresectable hepatocell...
PURPOSE: Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chance...
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mo...
Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any speci...
BACKGROUND: Although sorafenib is accepted as the standard of care in advanced hepatocellular carcin...
BACKGROUND & AIMS: Sorafenib is the recommended treatment for patients with advanced hepatocellular ...
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
Aim: Sorafenib efficacy and safety in advanced hepatocellular carcinoma (HCC) have been demonstrated...
Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Becaus...
Background & AimsThe Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP)...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/135309/1/hep28881-sup-0001-suppinfo.pdf...
Purpose: Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) tri...
BACKGROUND: Prior to the 2008 advent of sorafenib, traditional cytotoxic agents were the therapeutic...
BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHAR...
Introduction: Sorafenib was the first therapy used for systemic treatment of unresectable hepatocell...
PURPOSE: Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chance...
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mo...
Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any speci...
BACKGROUND: Although sorafenib is accepted as the standard of care in advanced hepatocellular carcin...
BACKGROUND & AIMS: Sorafenib is the recommended treatment for patients with advanced hepatocellular ...
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
Aim: Sorafenib efficacy and safety in advanced hepatocellular carcinoma (HCC) have been demonstrated...
DOI
Add to ORKG